Thank you, welcome to BioArctic's full year report for 2020. I'm Gunilla Osswald, and I'm the CEO of BioArctic. I will share this presentation today with our CFO, Jan Mattsson. 2020 was a very good year for BioArctic, in spite the tough situation around us with the COVID-19 pandemic. Our great project portfolio progressed well, thanks to our great personnel and our great partners. Eisai has during 2020 broadened the scope for lecanemab, BAN2401, and has now two phase III programs ongoing. Yesterday, we also announced that the number of patients in CLARITY AD, the pivotal phase III study, has been increased to ensure a robust data set. We have also reported further data from the open label extension study that continues to strengthen the support for lecanemab during the last year. Next slide, please. BioArctic is listed on Nasdaq Stockholm Mid Cap, and this is our disclaimer. Next slide, please. BioArctic is a unique Swedish biopharma company, and our aim is to improve lives for patients with central nervous system disorders. When I say unique Swedish biopharma company, I mean that on four different aspects. The first one is that we are focusing on areas where there is a high unmet medical need. That's areas like Alzheimer's disease and Parkinson's disease, where today only have symptomatic treatments for the patient. We focus on disease modifying treatments meant to affect the underlying disease. These groups of patients are huge, and there is a large commercial opportunity. The second aspect is that we have a great organization with very experienced and engaged coworkers and important fruitful collaborations with both universities and with our strategic partners, Eisai in Alzheimer's disease and AbbVie in Parkinson's disease. The third aspect is that we have an attractive and well-balanced project portfolio, where projects spanning all the way from early discovery all the way to phase III. We have partnered projects that generate revenues by milestones, where our strategic partners carry the cost for the clinical trials, and we have earlier fully owned projects with substantial marketing and out licensing potential. The fourth aspect is that we are well-financed. We have a strong cash position of approximately SEK 1 billion from the bank or more than $120 million. We have valuable collaboration agreements with big pharma like Eisai and AbbVie at the value of up to SEK 8.7 billion, about $1 billion, plus royalties if we come all the way to the market. BioArctic is a dynamic and very exciting company with a huge potential that I'm pleased to lead. Next slide, please. I'll start with some highlights of the last year. We had significant progress in the projects, both in Alzheimer's disease, and the rest of the portfolio. If we start with lecanemab, Eisai has presented new data from the ongoing phase IIb open label extension study at several Alzheimer's congresses last year. The latest one was at CTAD Congress in November. This further strengthens the support for lecanemab. I'll come back to that. The second aspect for lecanemab is the ongoing CLARITY AD study for early AD patients, where the phase III pivotal program progressed well during the year. I have to say that I'm really impressed with how Eisai has worked with mitigating the potential impact of COVID-19 on the study last year, and continue to do so, and put the safety of the patients first, and also doing a lot of efforts to secure high data quality. The third aspect for lecanemab last year was that an additional phase III program was started, and that is called AHEAD 3-45, started in September in collaboration with Alzheimer's Clinical Trials Consortium. This phase III program here, lecanemab is given to very early stages of Alzheimer's disease. In Parkinson's disease, AbbVie canceled the second part of the phase I program, the multiple ascending dose study with ABBV-0805. The phase I program is still ongoing with single doses. They are instead working on a detailed plan for phase II, and we think that was very good news that they are planning for phase II. If we look at our internal programs, they have also continued to progress well in spite of the COVID-19 pandemic situation. We have added two innovative projects to the portfolio, and they are progressing really well now, well underway. At the end of last year, we also won the Allbright Award for companies who are listed at Nasdaq Stockholm. They are being reviewed for how they work with gender equality and leadership, and we were pleased to see that we won this award this year for last year. Next slide, please. If we focus on what happened during the fourth quarter of last year, BAN2401 got its INN name, so we now should say lecanemab. I will try to use that, and sometimes I might slip and say BAN2401 again, but we mean lecanemab. At the CTAD Congress, there were three different presentations. The first one was on Clarity AD, where baseline characteristics of the patients were reviewed and compared with phase II. Importantly, they were consistent. It's also representative of an early AD population, so that was really good news. The second one was two presentations on the open-label extension study. They showed that first, there was a rapid decrease of clearing amyloid from the brain. Where there was shown already after three months of treatment with lecanemab in the patients who earlier got placebo in the core study. Then a further continuous decrease was seen at six months, and further after 12 months. The second aspect that was reported was that if you focus on the side effects, and especially the ARIA-E, which is like a brain edema, which mainly is seen on MRI scans. They still report a very low frequency of the side effect, which is consistent with previously reported in the core study. This is one of the areas which differentiates lecanemab from other late-stage competitors who have more ARIA-E in spite of that they have to titrate and give the dose slowly increasing upwards. Lecanemab does not need to titrate. You can give the top dose directly and still have less ARIA-E, as shown in the phase IIb open-label extension study and in the phase IIb core study. The next presentation also at the CTAD Congress was AHEAD 3-45. This study, ACTC presented the study design and also some baseline data on the first patients who were screened. After this period, I think last year was a really good year, and this year has also started in a very good way. It started with that we got a European patent granted for antibodies targeting truncated forms of amyloid beta. Yesterday we had a press release about that Eisai has expanded the Clarity AD study by approximately 200 patients. This is in order to ensure a robust data set and mitigating that some of the patients missed some doses during the first wave of COVID-19 pandemic situation last year. The recruitment has gone really well, and the recruitment, including additional patients, have now been closed. The screening phase is ongoing. We expect randomization to be concluded during February. At Eisai, I'm really impressed with how they are driving this program. They still expect the 18-month readout in September of 2022. Next slide, please. BioArctic has an attractive and well-balanced project portfolio. We have organized it in five focus areas. Alzheimer's disease, Parkinson's disease, other CNS disorders, our blood-brain barrier technology, and diagnostics. I think it's balanced in three different ways. We have several projects in different areas. We have projects spanning from discovery all the way to phase III. We have a combination of fully financed partnered projects and innovative, fully owned early programs. Our strategic partner finance the expensive clinical programs. We finance the less expensive preclinical phases where we can increase the value before partnering. During last year, we can notice that we have added a new phase III program for lecanemab in a new patient population. We can also see the two new discovery projects that was added to the portfolio late the year before. They have now started really well. I think with that, we have a really attractive project portfolio. Next slide, please. A couple of words about our long-standing and extensive successful partnerships. In Alzheimer's disease with Eisai since 2005. In this collaboration, we have had seven research collaborations and two license deals. Far, we have received EUR 65 million, and the total aggregated value of this is up to EUR 222 million. There's still a lot left if the programs continue to progress well. If we come all the way to the market, BioArctic will get royalties of substantial value. Could be like blockbuster revenues, which means that more than $1 billion per year without any cost for the clinical program. We also have the right to other indications outside of Alzheimer's disease, and we have also rights to commercialize lecanemab in the Nordic region. I think that BioArctic has a great business model, which is shown in this case. It's also shown in the case for Parkinson's, where we have a successful collaboration with AbbVie since 2016. So far, we have received $130 million out of the total aggregated value of the agreements of up to $755 million. Plus royalties if we come all the way to the market. If you think about this patient population, which also is huge, and especially if you also add other indications like multiple system atrophy and Lewy body dementia, this could also mean substantial revenues for BioArctic if it continues to progress well. It's two great collaborations that we are really, really happy about. Next slide, please. This slide shows the broad lecanemab clinical program that Eisai is driving. We start in the middle with the CLARITY AD phase III confirmatory study, which is in early AD patients, which means patients with mild cognitive impairment and mild Alzheimer's disease. This study is expected to read out, as I said, in September 2022, according to Eisai, and the new target of patients now is 1,766 early AD patients. It is also in the same patient population, the open label extension linked to the Phase IIb study, which is ongoing in 180 patients. Here we will see data. Since this is an open study, data will be coming along continuously and being reported at congresses. The next one to look out for is AD/PD. The new phase III program, AHEAD 3-45, is focusing on very early stages of Alzheimer's disease. This is comprising of two sub-studies, two sister trials, A3 and A45. It's driven together with Alzheimer's Clinical Trials Consortium. A total of approximately 1,400 subjects are expected to be included. This is for preclinical asymptomatic subjects who have intermediate or elevated amyloid levels in the brain. The A3 program, there the subjects have intermediate levels of amyloid in the brain, and here the intention is to delay the brain amyloid accumulation by lecanemab. In the A45 study, they have elevated levels of amyloid, and here the intention is to reduce the risk of cognitive decline. I'm really looking forward to the progress of this impressive broad program that Eisai is driving in Alzheimer's disease. Next slide, please. Our early-stage portfolio has also continued to develop in a very good way in spite of the COVID-19 pandemic situation. So far, we have managed to progress our early portfolio without any noticeable disturbances. The largest area we have is Alzheimer's disease, where we have four fully owned disease-modifying antibody projects. Each of those projects have different mechanisms from the others. As I said a year ago, I think within the coming year, I will reveal some more information about those programs. We have been very secret about them. What we have told is that AD1801 is a project which is linked to ApoE, which is the most common risk factor for Alzheimer's disease. We have also just recently now disclosed that AD1503, that project is linked to and have antibodies towards the truncated forms of Aβ. These truncated forms are prone to aggregate and form toxic aggregated forms of amyloid beta. Our antibody is intended to bind to those aggregated forms and eliminate them. We have also then the early Parkinson program together with AbbVie. Our new neurodegeneration program, as I said, has got a very good start. We are also preparing for Down syndrome in different ways. For example, there is a need for subcutaneous administration. We have to wait a bit further until that is time, but we have the poster presentation at CTAD about Down syndrome, for example. Our efforts in the blood-brain barrier technology platform is progressing really, really well. I'm really excited about this part. That's something for us to continue to talk more about at a later stage. Diagnostics, which is really important also when you look at early stages of Alzheimer's disease, and also to be able to both identify the patients and to follow disease progression. Here the whole field are also doing some very interesting breakthroughs that we will also follow at the next CTAD Congress. With that, next slide please, and I will hand over to our CFO, Jan Mattsson, for the financial summary. Thank you, Gunilla. For those of you that don't know us that well, I'd like to point out that we currently don't have any steady revenues, but have a business model focused on partnership agreements, which means that our financials are very much linked to milestones and that income is related to research projects with our partners. With that said, let's start looking at our net revenues and operating results. My comments relate to the quarter's numbers, not the full-year numbers. Net revenues were SEK 8 million for the quarter compared to SEK 26 million same period last year. The change is primarily related to lower activity in the Parkinson's disease program and is according to plan. Looking at OpEx. Total costs are down SEK 8 million from SEK 40 to SEK 32, this is mainly due to lower project expenses compared to last year, although expenses in our own projects increased during the same period due to higher activity. Moving to operating loss, it was down to -SEK 13 million in the quarter compared to SEK 31 in Q4 of last year. Just as for net revenues, this relates to lower activity in the Parkinson's disease program. Our cost forecast for the coming 12 months is in the range of SEK 180 million-SEK 220 million. Next slide, please. Looking at cash and net results. The cash balance continues to be in good health and amounted to SEK 1 billion at the end of the quarter. Our cash flow from operating activities was -SEK 25 compared to -SEK 54 in Q4 of last year. The net result for the period was -SEK 13 compared to -SEK 70 million same quarter last year. In summary, we continue to be in good financial shape. With that, I hand back to you, Gunilla. Next slide, please. Then I will conclude today's presentation with some upcoming news and some closing remarks. Next slide, please. Now we are on slide 14. The upcoming news that we are looking forward to now is, of course, to see that lecanemab is progressing well. We're looking forward to the next Alzheimer's Congress, AD/PD, in March. It's again a virtual congress. There are presentations on lecanemab. Also BioArctic has a poster on Down syndrome. I think that the whole Alzheimer arena is, of course, evolving a lot. Of course, everyone is excited to follow the FDA decision on aducanumab, which now has extended review period until the 7th of June. The whole progress also with regard to diagnostics is also something that we look forward to follow at the AD/PD congress. In Parkinson's disease, we look forward to the continued phase I study that AbbVie is driving and the preparation for the phase II program. That will still take some time. The diagnostic area has great progress in the AD field, and I'm really eager to follow blood biomarkers like p-tau217, and I think this can really help the Alzheimer's field if that continues to look as well as we have seen previously. We are concluding that we have had a very good year, 2020, and we have very exciting times ahead. Next slide, please. Just conclude today's presentation and say that BioArctic is built on great science. We have great projects. It's driven by great people. Everything we do is with patients in mind. We really want to help them to get better life. Next slide, please. By that, I thank you for your attention, and we're happy to take some questions. Thank you. If you wish to ask an audio question, you may do so by pressing zero one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing zero two to cancel. Once again, please press zero two on your telephone keypad if you wish to ask an audio question. Our first question comes from Joseph Hedden from Rx Securities. Please go ahead. Good morning, thanks for taking my question. I have a few. Starting on your alpha-synuclein mAb program. You mentioned the single ascending dose study is ongoing. Has AbbVie given you any indication of the recruitment status of that and when we might expect to see results? In terms of the plans for phase II, have you had any interactions with AbbVie at all on the design or the ongoing conversations on design and when we might see an announcement on that? Thank you so much, Joseph. Great questions. With regard to ABBV-0805, which is driven by AbbVie, the singular ascending dose study is ongoing and is looking really, really well, is what I can say. I can't disclose details, but I can just say that it's going really well. That they are preparing for phase II, and that will still take some time because, I mean, it's a lot of things to prepare when you go into a phase II program. I think just want to manage your expectations and say don't expect it before summer. Okay. Yeah. Okay. Of course we are engaged with AbbVie. That was your other question. Of course, we are. I mean, the way we work, it's they who are driving it, but we are working with joint steering committee, joint development committees, and so forth. Okay, great. Of course, we are. Okay, great. Thank you. Just staying on that program. We saw yesterday Biogen sneaked into their results annual full year 2020 results that their program had failed in phase II. I just wondered if you could remind us about how 0805 is differentiated from Biogen's lecanemab There was some news yesterday. We really look forward to seeing more data. The first one of the alpha-synuclein antibodies that had some phase II data is Roche's prasinezumab. We're really looking forward to seeing more data on that program at AD/PD. They seem to have had some effect on the movement part of UPDRS. I'm really looking forward to learning more from their study. I'm also eager to understand more about the Biogen phase II study. I think it's important to understand that each antibody is different. Each is unique. They are all targeting alpha-synuclein in different ways. What we believe is that we have the most selective antibody. We're selectively targeting the protofibril oligomers of alpha-synuclein. This is really important not to have too much binding to monomers, because then it can be sequestrated in the periphery. We are eager to learn more about the other competitors and their phase II programs, and to understand what learnings we can draw from that. The same approach has been in Alzheimer's disease for many years, where we have learned a lot in the different clinical trials. Eventually, we now have seen, for example, lecanemab, who has had really encouraging results in patients. Just curious, is there the same kind of evidence in Parkinson's disease as in Alzheimer's disease that the oligomers and protofibrils are the most neurotoxic and therefore potentially the best to target with an antibody? Is it more a case in Parkinson's that you do get sequestering of the antibodies by monomers in the blood? No, our belief is strongly that it is the protofibrils who is the most toxic part. That's why our focus has been to have very selective antibodies targeting the toxic protofibrils in the brain. We have a very similar thinking on that aspect between 0805 and lecanemab. That is the toxic protofibrils that we are targeting. Here we differ a bit from some of the competitors. Okay, great. That's interesting. Thanks. Just perhaps one on the finances. You issued OpEx guidance today. It was slightly lower than we were expecting for this year. Does it assume that any of your proprietary projects are going into clinical trials this year? I think the guidance we can give that don't expect any of our internal programs to go into clinical trials this year. Okay. Thanks very much, Gunilla. Thank you. Our next question. Thank you, Joseph. Great questions as always. Thank you. Our next question comes from Gagan Almqvist from Redeye. Please go ahead. Hello. I have a question about the two compounds in discovery stage still, the one for which you got a patent, the AD1503. What's the mechanism of action? How is it different from lecanemab? Also about the AD1801. Could you elaborate so I understand difference between these mechanisms of action? Thank you so much, Gagan. Long case. Yes. I tried to Google it and search it. I couldn't find anything on the topic. No. We are deliberately quite still secretive about what we are saying since it's a very competitive area, as you know. Okay. If we start with AD1503, where we also revealed that we have. Patent The concept patent for the truncated Aβ antibodies approved in Europe. I think that this antibody targets the truncated forms of amyloid, which are very prone to aggregate and form protofibrils and fibrils and plaques. Our antibody binds to the truncated forms in this respect. Lilly's antibody, donanemab, has to some extent, some similarities with this form. They showed the positive phase II results now, 11th of January. We have some similarities, and we believe that we also have some important differences that I'm not going to reveal. I think that's an exciting program that we are progressing further. The other program that we also have revealed a bit about our target is AD1801, which is linked to ApoE. ApoE is the most common risk factor for Alzheimer's disease patients. This is also a hot target, if you will. I'm not going to reveal any details more than saying that our antibodies are linked to, I can say, the fragments of ApoE, which are toxic. More than that, I'm not going to reveal. I think it's important to understand, we have lecanemab. Of course, we strongly believe and stand behind lecanemab. There is a huge population out there who desperately needs more and better medicines. There is a desperate need for disease-modifying treatment. Our aim is to continue to develop further disease-modifying treatments with different mechanism of action. We can provide different options for the patients and also opportunities for combination therapies in the future. I think it's really important, even though we see very encouraging results now with, for example, lecanemab. It's really important that the whole field, including BioArctic, continues to drive new innovative treatments as well. As you know, we have four different programs, and we have now revealed two of those mechanisms. Okay. Thank you. Thank you, Gagan. Thank you. Just as a reminder, if you wish to ask an audio question, you may do so by pressing zero one on your telephone keypad. Once again, please press zero one on your telephone keypad if you wish to ask an audio question. Okay. There appears to be no further questions, so I'll hand back to the speakers for any other remarks. I just want to say thank you very much for your attention and thank you for great questions. I wish you a great day and stay safe.